|
US2009281075A1
|
|
Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
|
|
AR070299A1
|
|
DERIVATIVES OF PIRAZOLOPIRIMIDINAS AS INHIBITORS OF CYCLININE DEPENDENT KINASES, USES AND PHARMACEUTICAL COMPOSITIONS
|
|
WO2009048474A1
|
|
2,7,9-substituted purinone derivatives for immunosuppression
|
|
WO2008043031A1
|
|
6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
|
|
WO2008043019A1
|
|
8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
|
|
US2008051423A1
|
|
Nitrogen heterocycle biaryls for osteoporosis and other diseases
|
|
US2011071130A1
|
|
2-aminobenzimidazoles for treating neurodegenerative diseases
|
|
EA014907B1
|
|
8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
|
|
AU2006283109A1
|
|
Alpha2C adrenoreceptor agonists
|
|
US2008146536A1
|
|
2-Aminoimidazopyridines for treating neurodegenerative diseases
|
|
BRPI0611348A2
|
|
compound, pharmaceutical formulation, method for diuresis or treatment of a disorder, and use of a compound
|
|
EP1874772A1
|
|
Purine and imidazopyridine derivatives for immunosuppression
|
|
CN101203516A
|
|
Purine and imidazopyridine derivatives for immunosuppression
|
|
AU2006214380A1
|
|
Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
|
|
CA2611971A1
|
|
Nitrogen heterocycle biaryls for osteoporosis and other diseases
|
|
US2005239770A1
|
|
N-heterocyclic inhibitors of TNF-α expression
|
|
WO2005114198A2
|
|
Protein phosphorylation assay
|
|
US2005222203A1
|
|
Nitrogen heterocycle biaryls for osteoporosis and other diseases
|
|
US7161003B1
|
|
Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
|
|
CA2457408A1
|
|
System and method for aqueous solubility prediction
|
